Bristol Myers Squibb Highlights Five Positive Phase 3 Trials for SystImmune-Developed ADC Iza-Bren

New data showed the treatment improved outcomes for patients with certain lung and breast cancers, adding momentum to its global development across multiple hard-to-treat cancer types. The results further strengthen confidence in the therapy’s potential to expand treatment options for cancer patients.